AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10714728
Drug: Metoprolol CR/XL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol CR/XL (25 mg once per day for NYHA class II or 12.5 mg once per day for NYHA class III or IV, titrated up to 200 mg once per day)
Trial: 23087948
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C supplementation (dosage not specified, but mentions up to 10 g/day and 5 g/day as safe)
Trial: 23087948
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C supplementation (megadose therapy)
Trial: 23087948
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C supplementation (up to 5 g/day)
Trial: 3816292
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg cimetropium bromide
Trial: 3816292
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg cimetropium bromide
Trial: 31992403
Drug: Both therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both therapies (MAD and CPAP)
Trial: 25246305
Drug: Oral dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dexmedetomidine 2 µg/kg (Group D1)
Trial: 25246305
Drug: Oral dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dexmedetomidine 3 µg/kg (Group D2)
Trial: 25246305
Drug: Oral chloral
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral chloral hydrate 50 mg/kg (Group C1)
Trial: 25246305
Drug: Oral chloral
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral chloral hydrate 100 mg/kg (Group C2)
Trial: 21697250
Drug: Cholecalciferol (4,000-40,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol (4,000-40,000 IU/d) plus calcium (1200 mg/d), followed by equilibration to 10,000 IU/d
Trial: 17302076
Drug: 0.125% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.125% bupivacaine plus clonidine, continuous infusion 10 mL x h(‐1)
Trial: 17302076
Drug: 0.0625% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.0625% bupivacaine plus clonidine, continuous infusion 10 mL x h(‐1)
Trial: 17302076
Drug: 0.125% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.125% bupivacaine plus clonidine, PCA system 5 mL every 30 minutes
Trial: 17302076
Drug: 0.0625% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.0625% bupivacaine plus clonidine, PCA system 5 mL every 30 minutes
Trial: 17302076
Drug: 0.125% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.125% bupivacaine plus clonidine, continuous infusion 5 mL h x (‐1) plus PCA 2.5 mL every 30 minutes
Trial: 17302076
Drug: 0.0625% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.0625% bupivacaine plus clonidine, continuous infusion 5 mL h x (‐1) plus PCA 2.5 mL every 30 minutes
Trial: 12699211
Drug: Monthly physician
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly physician visits
Trial: 12699211
Drug: Semiannual physician
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Semiannual physician visits and monthly nurse phone calls
Trial: 10849265
Drug: kurorinone 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: kurorinone 400 mg daily for 3 months
Trial: 10849265
Drug: interferon-alpha (IFN-alpha)
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: interferon-alpha (IFN-alpha) 3 million units daily for 1 month, every other day for 2 months for 3 months
Trial: 8256707
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (other antiarrhythmic drug therapy)
Trial: 28612668
Drug: Melatonin 20
RxNorm normalized name: melatonin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 20 mg as a single dose
Trial: 28612668
Drug: Antibiotics only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics only (Control)
Trial: 27481077
Drug: Salmeterol 50
RxNorm normalized name: FLUTICAS 100/SALMETEROL 50 INHL DISK 14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol 50 µg/Fluticasone 500 µg combination (SF Group)
Trial: 27481077
Drug: Tiotropium 18
RxNorm normalized name: TIOTROPIUM 18MCG CAP,INHL,6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium 18 µg (T Group)
Trial: 23518801
Drug: Phenylephrine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine infusion (PE)
Trial: 18996241
Drug: Therapy Assistant
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy Assistant WREX
Trial: 16478747
Drug: MDM2-SNP309 (T/G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDM2-SNP309 (T/G or G/G genotype)
Trial: 16478747
Drug: Comparison between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison between T/T genotype and MDM2-SNP309 (T/G or G/G genotype)
Trial: 3063045
Drug: Midazolam 0.1
RxNorm normalized name: midazolam 0.1 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.1 mg/kg i.v. and a supplementary 0.025 mg/kg every second min until sleep or dysarthria, followed by paracervical blockade with 1% mepivacaine 10 ml on each side of the portio
Trial: 3063045
Drug: Fentanyl 2.5
RxNorm normalized name: fentanyl 2.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 2.5 micrograms/kg and thiopentone 2 mg/kg i.v. with supplementary thiopentone 50 mg every 15 s until loss of the eyelid reflex, maintained with nitrous oxide in oxygen 2/1 and supplementary thiopentone 50 mg as required
Trial: 31470005
Drug: Subcutaneous vedolizumab
RxNorm normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous vedolizumab 108 mg every 2 weeks
Trial: 31470005
Drug: Intravenous vedolizumab
RxNorm normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous vedolizumab 300 mg every 8 weeks
Trial: 31470005
Drug: Subcutaneous vedolizumab
RxNorm normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous vedolizumab
Trial: 28479255
Drug: Topical benzoyl
RxNorm normalized name: benzoyl peroxide Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical benzoyl peroxide 5% and clindamycin 1.2% (BPO/C) gel applied every night before surgery
Trial: 28479255
Drug: Topical benzoyl
RxNorm normalized name: benzoyl peroxide Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical benzoyl peroxide 5% and clindamycin 1.2% (BPO/C) gel applied once before surgery
Trial: 28479255
Drug: Topical benzoyl
RxNorm normalized name: benzoyl peroxide Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical benzoyl peroxide 5% and clindamycin 1.2% (BPO/C) gel
Trial: 28479255
Drug: Topical benzoyl
RxNorm normalized name: benzoyl peroxide Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical benzoyl peroxide 5% and clindamycin 1.2% (BPO/C) gel with >1 application
Trial: 22653374
Drug: Web-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based intervention (daily education about sitting correctly and video demonstrations of exercises)
Trial: 21212755
Drug: Atorvastatin and
RxNorm normalized name: atorvastatin and ezetimibe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin and antioxidants (vitamins E+C)
Trial: 19720877
Drug: PH-797804 (N-phenyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PH-797804 (N-phenyl pyridinone p38 MAP kinase inhibitor)
Trial: 17251533
Drug: Interferon beta‐1b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon beta‐1b treatment
Trial: 17251533
Drug: Presence of
RxNorm normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presence of anti‐MOG and anti‐MBP antibodies
Trial: 15482993
Drug: Iomeprol 400
RxNorm normalized name: Iomeprol 400 MG/1 ML Injection Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iomeprol 400 mg ml(‐1) (98 ml, injection rate 5 ml s(‐1))
Trial: 15482993
Drug: Iomeprol 300
RxNorm normalized name: Iomeprol 300 MG/1 ML Injection Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iomeprol 300 mg ml(‐1) (130 ml, injection rate 5 ml s(‐1))
Trial: 9757156
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion of 15 ng/kg body weight/min urodilatin
Trial: 9757156
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion of 22.5 ng/kg body weight/min urodilatin
Trial: 2114782
Drug: Immediate, prehospital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate, prehospital treatment initiation with rt-PA (recombinant tissue-type plasminogen activator)
Trial: 2114782
Drug: Delayed, in-hospital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed, in-hospital treatment initiation with rt-PA
Trial: 29283786
Drug: Topical Dexamethasone
RxNorm normalized name: dexamethasone Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Dexamethasone 1% (Group DEX)
Trial: 26622431
Drug: Low-dose 90Sr-90Y
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose 90Sr-90Y therapy combined with 0.5% timolol maleate solution
Trial: 26622431
Drug: Physiological saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiological saline with identical dose of 90Sr-90Y
Trial: 11220420
Drug: Pancuronium for
RxNorm normalized name: pancuronium
DrugBank: Pancuronium (DB01337)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pancuronium for both doses (Group PP)
Trial: 7950181
Drug: No. 90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No. 90 Dasheng Jiangya (DSJY) oral liquid
Trial: 27065308
Drug: Nutrition education
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutrition education (NEd) using Health Belief Model (HBM), provided twice monthly for 6 months to the intervention group (n = 80)
Trial: 22961605
Drug: Acupuncture (AC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture (AC) administered in 20 sessions over 10 weeks
Trial: 22961605
Drug: Tanacetum (TAN)
RxNorm normalized name: Tanacetum cinerariifolium flower
DrugBank: Tanacetum cinerariifolium flower (DB10975)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tanacetum (TAN) at 150 mg/day
Trial: 22961605
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (AC+TAN)
Trial: 16167916
Drug: Raloxifene hydrochloride
RxNorm normalized name: Raloxifene Hydrochloride
DrugBank: Raloxifene (DB00481)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Raloxifene hydrochloride (60 mg/day) plus calcium (500 mg/day)
Trial: 12763376
Drug: Lamivudine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamivudine (100 mg) for 52 weeks
Trial: 8843176
Drug: Urapidil 60
RxNorm normalized name: urapidil 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urapidil 60 mg twice per day
Trial: 8843176
Drug: Atenolol 50
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 50 mg once per day
Trial: 1321894
Drug: Half-dose chemotherapy
RxNorm normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-dose chemotherapy (50% dose reduction of all chemotherapeutic agents)
Trial: 1321894
Drug: Full-dose chemotherapy
RxNorm normalized name: Rho(D) immune globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose chemotherapy (in older children)
Trial: 24810491
Drug: Early ART
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early ART (starting after 2 weeks of tuberculosis treatment)
Trial: 24810491
Drug: Delayed ART
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delayed ART (placebo, then starting ART at the end of 6 months of tuberculosis treatment)
Trial: 21822762
Drug: Parent training
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent training (PT) added to antipsychotic medication
Trial: 21822762
Drug: Antipsychotic medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic medication plus PT
Trial: 11803730
Drug: Celecoxib 100
RxNorm normalized name: celecoxib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 100 mg/day
Trial: 9667265
Drug: Thoracic radiation
RxNorm normalized name: Thoracol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic radiation therapy starting on day 1 of chemotherapy (arm I)
Trial: 9667265
Drug: Thoracic radiation
RxNorm normalized name: Thoracol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic radiation therapy starting on day 64 of chemotherapy (arm II)
Trial: 7830803
Drug: New biscuit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New biscuit (25 biscuits of 15.5 g each in 2 weeks)
Trial: 2974715
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy of cilazapril and propranolol
Trial: 334185
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg of aspirin
Trial: 27655517
Drug: Professional oral
RxNorm normalized name: Dentek Professional Oral Care Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Professional oral health care (POHC) and Mucosamin® during recovery after transplantation
Trial: 20829713
Drug: Olmesartan medoxomil
RxNorm normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olmesartan medoxomil (O) 10 mg once-daily, with possible dose increase to 40 mg
Trial: 20829713
Drug: Ramipril (R)
RxNorm normalized name: Ramipril
DrugBank: Ramipril (DB00178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ramipril (R) 2.5 mg once-daily, with possible dose increase to 10 mg
Trial: 18533736
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination therapy with statins (e.g., niacin/lovastatin, ezetimibe/simvastatin, amlodipine/atorvastatin)
Trial: 18533736
Drug: Aspirin/pravastatin
RxNorm normalized name: ASPIRIN/PRAVASTATIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin/pravastatin
Trial: 15919088
Drug: 1000 microg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 microg of rectal misoprostol administered by traditional birth attendants (TBAs) in the intervention area.
Trial: 15919088
Drug: Non-intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-intervention group (no misoprostol treatment, referred to nearest facility).
Trial: 14655926
Drug: 2.5-mg slow-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5-mg slow-release melatonin
Trial: 14655926
Drug: 10-mg melatonin
RxNorm normalized name: melatonin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-mg melatonin
Trial: 6144462
Drug: Diazepam 5.0
RxNorm normalized name: DIAZEPAM 5.0 mg in 1.0 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 5.0 mg
Trial: 6144462
Drug: Lorazepam (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam (various doses)
Trial: 30276500
Drug: Erenumab 140
RxNorm normalized name: Erenumab 140 mg/mL solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erenumab 140 mg (CM)
Trial: 22474401
Drug: Nifedipine-telmisartan combination
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine-telmisartan combination treatment
Trial: 21313903
Drug: pethidine +
RxNorm normalized name: pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pethidine + ketamine (5 mg pethidine and 0.25 mg kg(‐1) ketamine)
Trial: 21313903
Drug: pethidine +
RxNorm normalized name: pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pethidine + placebo (10 mg pethidine and NS)
Trial: 18037745
Drug: Transthoracic Doppler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transthoracic Doppler echocardiography with intravenous administration of adenosine (0.16 mg.kg(‐1).min(‐1))
Trial: 11111290
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen therapy (HBO) in addition to relief of weightbearing structures (Gr. II)
Trial: 8868017
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulfate regimen
Trial: 8868017
Drug: Intramuscular magnesium
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular magnesium sulfate regimen
Trial: 1299709
Drug: Regimen A,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen A, standard dosage of clofazimine (CLO) in multidrug therapy (MDT) regimen
Trial: 1299709
Drug: Regimen B,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen B, CLO 600 mg once every 4 weeks
Trial: 1299709
Drug: Regimen C,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen C, CLO 1200 mg once every 4 weeks
Trial: 6608419
Drug: Potassium cardioplegic
RxNorm normalized name: Potassium
DrugBank: Potassium (DB14500)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium cardioplegic solutions with added blood (group B)
Trial: 30628813
Drug: Naltrexone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (50 mg for five days)
Trial: 26391511
Drug: Acceptance and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance and commitment therapy with weekly mobile phone messages for three months
Trial: 18336488
Drug: Intensive drug
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive drug administration teaching using an online module and high fidelity simulation
Trial: 10699339
Drug: Trivalent cold-adapted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent cold-adapted influenza vaccine
Trial: 9200764
Drug: Levomepromazine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levomepromazine (50 mg/day)
Trial: 9200764
Drug: Thioridazine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thioridazine (50 mg/day)
Trial: 3882371
Drug: New device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New device for giving multiple injections of short‐acting insulin
Trial: 3882371
Drug: Conventional syringes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional syringes for injections of short‐acting insulin
Trial: 27468542
Drug: Qingxue Dan
RxNorm normalized name: Dan shen suan b
DrugBank: Salvianolic acid B (DB19313)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qingxue Dan (QXD) 900 mg/d for 8 weeks
Trial: 24509284
Drug: Hypothermia induced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypothermia induced by rapid infusion of 600 to 2,000 ml cold saline and endovascular cooling
Trial: 17556425
Drug: 2 l
RxNorm normalized name: H-2 locus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 l fill of dialysate
Trial: 17556425
Drug: 3 l
RxNorm normalized name: D3 Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 l fill of dialysate
Trial: 11942049
Drug: Intermittent maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent maintenance chemotherapy
Trial: 9467547
Drug: Risedronate 5
RxNorm normalized name: risedronate 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate 5 mg cyclic
Trial: 9467547
Drug: Risedronate 5
RxNorm normalized name: risedronate 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate 5 mg daily and cyclic
Trial: 2529410
Drug: Ethanol solution
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethanol solution (0.5 g ethanol/kg B.Wt.)
Trial: 676644
Drug: Intravenous naloxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous naloxone (0.04 mg increments every 3 min) until ET(CO2) < 8% (group I)
Trial: 676644
Drug: Intravenous naloxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous naloxone (0.04 mg increments every 3 min) until ET(CO2) < 6.5% (group II)
Trial: 676644
Drug: Intravenous naloxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous naloxone (0.04 mg increments every 3 min) + additional intramuscular naloxone (group III)
Trial: 676644
Drug: Intravenous naloxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous naloxone (0.04 mg increments every 3 min) + additional intramuscular naloxone (group IV)
Trial: 21244446
Drug: Intra‐articular 70%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra‐articular 70% ethyl alcohol in combination with 2 percutaneously placed transarticular lag screws (EA‐TLS)